Laboratorios Farmaceuticos Rovi, SA Financials

Market Capitalization €2.87 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	20.59
Forward PE	20.74
Price to Sales TTM	€3.75
Price to Book MRQ	€4.87
Enterprise to Revenue	3.76
Enterprise to EBITDA	14.16

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	18.25%
Operating Margin	14.76%
Return on Assets TTM	14.32%
Return on Equity TTM	24.93%

Income Statement

Revenue TTM	€767,465,984
Revenue per Share TTM	€15.00
Quarterly Revenue Growth	2.50%
Gross Profit TTM	€472,438,016
EBITDA	€310,572,000
Net Income to Common TTM	€140,020,992
Diluted EPS TTM	€2.73
Quarterly Earnings Growth YoY	21.00%

Balance Sheet

Total Cash MRQ	€29,306,000
Total Cash per Share MRQ	€0.57
Total Debt MRQ	€
Total Debt to Equity MRQ	18.08
Current Ratio MRQ	3.71
Book Value per Share MRQ	€11.53

Cash Flow

Operating Cash Flow TTM	€141,578,000
Levered Free Cash Flow TTM	€47,381,500

ROVI Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	51,149,498
Float Shares	18,746,291
Avg 10 Volume	108,384
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	63.25%
% Held by Institutions	16.80%

Stock Price Summary

Beta	0.45
Fifty Two Week Low	€45.52
Fifty Two Week High	€89.50
Fifty Two Week Change	-50.80%
Day 50 MA	€53.69
Day 200 MA	€59.96

Dividends and Splits

Forward Annual Dividend Rate	€4.41
Forward Annual Dividend Yield	7.86%
Trailing Annual Dividend Rate	€1.10
Trailing Annual Dividend Yield	1.96%
Payout Ratio	40.39%
Dividend Date
Ex Dividend Date	2025-07-14
Last Split Factor
Last Split Date